

2021 Antibigram Inpatient Providers (January-December)

Relative Cost Per Day PO/IV ²	\$\$\$	\$	\$	\$	\$	\$	\$	\$	\$\$\$	\$\$\$	\$	\$\$\$	\$\$\$	\$\$\$ IV	\$	\$	\$\$\$
Gram Negative Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Amikacin	Ampicillin	Amp/sulbactam	Cefazolin ³	Cefoxitin	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Meropenem	Levofloxacin	Pip/Tazobactam	Tobramycin	Trimethoprim/sulfa	Nitrofurantoin Urinary Tract Infections only	Cefepime	Aztreonam ⁶
<i>Escherichia coli</i> (2191)	100	65	71	94 ³	94	99	96	90	95	100	90	98	95	86	97	-	-
<i>Enterobacter species</i> (161)	100	-	-	0	0	88	85	99	99	100	98	86	99	93	25	-	-
<i>Klebsiella species</i> (476)	100	0	82	91 ³	96	96	93	93	96	100	94	97	94	88	37	-	-
<i>Proteus species</i> (189)	100	78	92	98 ³	97	99	99	91	98	100	92	100	98	90	0	-	-
<i>Pseudomonas aeruginosa</i> (187)	100	-	-	-	-	91	-	94	98	97	89	95	100	-	-	96	69

Relative Cost Per Day PO/IV ²	\$	\$	\$	\$	\$	\$\$\$	\$	\$\$\$	\$	\$	\$	\$	\$	\$	\$\$\$ IV	\$\$\$	\$
Gram Positive Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Ampicillin	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Oxacillin ⁴	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/sulfa	Vancomycin	Nitrofurantoin Urinary Tract Infections only	
Methicillin Susceptible <i>Staphylococcus aureus</i> ⁴ (454)	-	-	-	78	66	100	91	100	100	0	-	-	93	97	100	98	
Methicillin Resistant <i>Staphylococcus aureus</i> ⁴ (228)	-	-	-	76	14	100	54	100	0	0	-	-	98	84	100	18/18	
<i>Staphylococcus coagulase negative</i> (358)	-	-	-	64↓	47↓	90	70	100	54	0	-	-	83	72↓	100	100	
<i>Enterococcus faecalis</i> (225)	100	-	-	-	-	-	76	100	-	99	-	-	-	-	100	100	
<i>Enterococcus faecium</i> ⁵ (42)	10/42	-	-	-	-	-	7/42	42/42	-	10/42	-	-	-	-	22/42	4/33	
<i>Streptococcus pneumoniae</i> ⁵ (31)	-	31/31	25/31	28/31	18/31	-	31/31	31/31	-	-	29/31	22/31	28/31	-	31/31	-	
<i>Streptococcus agalactiae</i> (Group B) ⁵ (27)	27/27	-	-	9/27	8/25	-	26/27	27/27	-	26/26	-	-	-	-	27/27	-	

- All data presented includes Springfield Hospital population.
- Relative Total Cost per Day PO/IV for Treatment: Green = Least expense, Red = Most expense
- Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI for *Escherichia coli*, *Klebsiella pneumoniae* or *Proteus mirabilis*.
- Oxacillin is tested as a surrogate for methicillin and nafcillin
- Trend assessment not provided due to low number of isolates.
- Aztreonam tested by manual method on *Pseudomonas aeruginosa* only.